# Pizarra — PT-pseudo_dcd61cf9b443 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_dcd61cf9b443
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 8.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.215 ng/mL²
  - PSA velocity: 1.64 ng/mL/yr
  - Prior PSA: 7.9 ng/mL
  - Prostate volume: 38.54 mL
  - Months since last PSA: 2
  - DRE findings: Suspicious (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.86351734 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD, Chronic kidney disease
  - Problem list / PMHx: COPD, Chronic kidney disease
  - Current medication: ciprofloxacine
  - Allergies: NKA
  - Additional notes: PSA 8.3 ng/mL. PI-RADS 5. PSAD 0.21. Prostate volume 39 mL. DRE suspicious. csPCa 0.86.

Vitals: weight 63 kg, height 170 cm, BMI 21.8, BP 111/75 mmHg, HR 73 bpm. Smoking: Ex-smoker (37 pack-yr, quit 2012).

Chief complaint: Assessment of a previously confirmed prostate malignancy alongside a continuously increasing PSA profile.

History: Initial evaluation for an elevated PSA occurred in early 2023, leading to active surveillance for a confirmed prostate malignancy. The individual is a 66-year-old retired primary school teacher, currently married but residing independently, with his wife acting as his main appointment liaison. Urinary complaints remain negligible, reflected by an IPSS score of 6, and he sustains a cycling habit of roughly 20 kilometres on two occasions each week. His medical background includes stable COPD and chronic kidney disease with a diminished eGFR, currently addressed via ciprofloxacin therapy. Recent encounters involved vascular surgery for varicose veins alongside a standard gastroenterology surveillance colonoscopy. Outside of urological matters, he experiences occasional mild insomnia but explicitly denies unexplained weight loss, skeletal discomfort, or haematuria. Morning appointments are preferred to align with public transit timetables. He maintains an ex-smoker status, having accumulated 37 pack-years before cessation in 2012.

Physical examination: DRE: The gland exhibits asymmetric enlargement, presenting a firm, irregular nodule within the left peripheral zone that aligns with a suspicious clinical impression. General inspection notes a well-nourished male with stable vital signs, absent palpable lymphadenopathy, and no hepatosplenomegaly. Abdominal palpation remains unremarkable, characterized by a soft, non-tender cavity without bladder distension.

Patient info: retired primary school teacher; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 33 units / week (heavy); exercise Cycling 2x/week, ~20 km; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Vascular surgery — varicose veins consult; Gastroenterology — surveillance colonoscopy.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.53 +/- 0.18   (95% CI 0.18-0.88)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.18  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 1.00 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with the current findings (PI-RADS 5, rising PSA), warrants a re-biopsy or deferral, as the initial panel is inconclusive. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA (8.3 ng/mL), PI-RADS 5, prior positive biopsy, PSA density (0.215 ng/mL²), and prostate volume (38.54 mL). It cannot account for the context provided by the mpMRI prose, the specific PSA velocity (1.64 ng/mL/yr), or the clinical context of the prior positive biopsy status.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a 53% probability, but the guideline criterion states the panel is undetermined. This suggests the prior failed to account for the critical ambiguity arising from the "prior positive biopsy" status. The guideline notes that the decision hinges on retrieved documents (prior grade, lesion change, surveillance pathway), which the prior ignored. Furthermore, the high aleatoric uncertainty (H=1.00) indicates the model cannot distinguish between the two outcomes based on the input features alone.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radiology Division | Erasmus MC | 10 January 2025
The gland spans 38.54 mL. A discrete focus measuring roughly 18 x 14 x 12 mm occupies the left peripheral zone, spanning base to mid-gland. T2 sequences highlight pronounced hypointensity there. Diffusion-weighted imaging confirms marked restriction, mirrored by diminished ADC signal. Post-contrast dynamics show brisk, localized enhancement compared to adjacent tissue.
get_psa_trend
[{"date": "Jan 2023", "val": 5.8}, {"date": "Jan 2024", "val": 3.7}, {"date": "Jan 2025", "val": 8.3}]
get_previous_notes
[{"date": "22 Jan 2024", "author": "Dr. C. Peters (GP)", "text": "Laboratory results today indicate a PSA concentration of 7.9 ng/mL, continuing an upward trajectory from the 6.2 ng/mL baseline documented in early 2023. A referral to the urology outpatient service has been processed for specialized evaluation and additional imaging. Routine pharmacotherapy will be maintained, with a routine check scheduled for the near future."}, {"date": "21 May 2024", "author": "Dr. C. Peters (GP)", "text": "Routine check on the ongoing urological workup. Serum PSA remains at 8.3 ng/mL, with attendance at the planned urology re-evaluation already arranged. Lifestyle factors, including alcohol consumption, were reviewed. Concurrent management of COPD and chronic kidney disease continues without alteration."}]

NOT RETRIEVED
The laboratory results panel was not retrieved because the moderator's agenda did not explicitly require it, and the retrieved documents provided sufficient context for the decision.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the left peripheral zone with brisk, localized enhancement.
- PSA trend: Serial PSA values show a significant rise from 3.7 ng/mL (Jan 2024) to 8.3 ng/mL (Jan 2025).
- Previous notes: The patient was under surveillance following a prior positive biopsy, and a re-evaluation was arranged.

AGAINST sampling this patient now:
- Previous notes: No documented prior ISUP grade or Gleason score was found in the retrieved notes.

WHERE THIS LEANS
The evidence strongly suggests a need for further tissue characterization due to the high-risk MRI finding (PI-RADS 5) and the rising PSA, despite the lack of prior grade information.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (high PI-RADS 5, rising PSA trend, and history of prior positive biopsy) strongly leans towards a biopsy, despite the lack of a documented prior Gleason score.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision leans towards biopsy because the retrieved evidence showed a high-risk PI-RADS 5 lesion and a significant rising PSA trend from 3.7 ng/mL to 8.3 ng/mL. Although no prior grade was documented, the combination of the high-risk imaging finding and the rising PSA trajectory, supported by the prior positive biopsy status, justifies further tissue characterization. The statistical prior suggested biopsy, and the retrieved documents confirmed the need for further sampling.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
